Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus | Zendy

Julien Hadoux | Zendy; Stéphane Vignot | Zendy; Thibault De La Motte Rouge | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus

Author(s) -

Julien Hadoux,

Stéphane Vignot,

Thibault De La Motte Rouge

Publication year - 2010

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s4482

Subject(s) - temsirolimus , renal cell carcinoma , medicine , mucositis , pneumonitis , sirolimus , rash , adverse effect , oncology , nivolumab , clinical trial , toxicity , intensive care medicine , immunotherapy , pi3k/akt/mtor pathway , cancer , discovery and development of mtor inhibitors , apoptosis , biology , lung , biochemistry

Metastatic renal cell carcinoma has harboured a poor prognosis for decades with immunotherapy being the only available therapy with high toxicity and modest effect. Dependance of renal cell carcinoma oncogenesis on the mTOR pathway has led to clinical development of temsirolimus in this setting. This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell carcinoma leading to an overall survival of 10.8 months in the pivotal phase III trial of this agent. Its specific adverse events consist of metabolic dysregulation (hyperlipemia, hyperglycemia), mucositis, rash and pneumonitis which can be severe and need careful monitoring and management. In this review, we will discuss of the clinical development of this molecule, its efficacy, its safety profile and future perspectives.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research